Cargando…
Safety of sildenafil in extremely premature infants: a phase I trial
OBJECTIVE: To characterize the safety of sildenafil in premature infants. STUDY DESIGN: A phase I, open-label trial of sildenafil in premature infants receiving sildenafil per usual clinical care (cohort 1) or receiving a single IV dose of sildenafil (cohort 2). Safety was evaluated based on adverse...
Autores principales: | Jackson, Wesley, Gonzalez, Daniel, Smith, P. Brian, Ambalavanan, Namasivayam, Atz, Andrew M., Sokol, Gregory M., Hornik, Chi D., Stewart, Dan, Mundakel, Gratias, Poindexter, Brenda B., Ahlfeld, Shawn K., Mills, Mary, Cohen-Wolkowiez, Michael, Martz, Karen, Hornik, Christoph P., Laughon, Matthew M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569839/ https://www.ncbi.nlm.nih.gov/pubmed/34741102 http://dx.doi.org/10.1038/s41372-021-01261-w |
Ejemplares similares
-
Physiologically-Based Pharmacokinetic Modeling Characterizes the CYP3A-Mediated Drug-Drug Interaction Between Fluconazole and Sildenafil in Infants
por: Salerno, Sara N., et al.
Publicado: (2020) -
Safety of sildenafil in premature infants at risk of bronchopulmonary dysplasia: Rationale and methods of a phase II randomized trial
por: Lang, Jason E., et al.
Publicado: (2022) -
Sildenafil and Retinopathy of Prematurity Risk in Very Low Birth Weight Infants
por: Samiee-Zafarghandy, Samira, et al.
Publicado: (2015) -
Safety of sildenafil in premature infants with severe bronchopulmonary dysplasia (SILDI-SAFE): a multicenter, randomized, placebo-controlled, sequential dose-escalating, double-masked, safety study
por: Schneider, Simone, et al.
Publicado: (2020) -
An opportunistic study evaluating pharmacokinetics of sildenafil for the treatment of pulmonary hypertension in infants
por: Thakkar, Nilay, et al.
Publicado: (2016)